What's in the pipeline?

被引：0
|
作者：
Belldegrun, A
机构：
来源：
PROSTATE CANCER AND PROSTATIC DISEASES | 1997年 / 1卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [31] The non-specialty pharmaceutical pipeline: What's on the horizon?
    Kaufman, Michele B.
    [J]. FORMULARY, 2010, 45 (11) : 360 - 360
  • [32] Pharmacologic management of primary sclerosing cholangitis: what's in the pipeline?
    Suri, Jaspreet
    Patwardhan, Vilas
    Bonder, Alan
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (08) : 723 - 729
  • [33] What's in the pipeline for hidradenitis suppurativa? Emerging and novel therapeutics
    Frew, J. W.
    Krueger, J. G.
    [J]. DRUGS OF THE FUTURE, 2021, 46 (01) : 43 - 60
  • [34] Biologics in the Dermatology: What's in the Pipeline for Atopic Dermatitis & Co?
    Bieber, T.
    [J]. ALLERGOLOGIE, 2022, 45 (04) : 290 - 290
  • [35] Emerging Treatment Strategies in Tourette Syndrome: What's in the Pipeline?
    Termine, Cristiano
    Selvini, Claudia
    Rossi, Giorgio
    Balottin, Umberto
    [J]. ADVANCES IN THE NEUROCHEMISTRY AND NEUROPHARMACOLOGY OF TOURETTE SYNDROME, 2013, 112 : 445 - 480
  • [36] Comment on Insulin Table 2018 What is important with the available Insulins? What's in the Pipeline?
    Duefer, M.
    Duefer-Kinzinger, A.
    [J]. DIABETES STOFFWECHSEL UND HERZ, 2018, 27 (03): : 179 - 180
  • [37] Treatment of Parkinson's Disease: What's in the Non-dopaminergic Pipeline?
    Hung, Albert Y.
    Schwarzschild, Michael A.
    [J]. NEUROTHERAPEUTICS, 2014, 11 (01) : 34 - 46
  • [38] Targets for Future Clinical Trials in Huntington's Disease: What's in the Pipeline?
    Wild, Edward J.
    Tabrizi, Sarah J.
    [J]. MOVEMENT DISORDERS, 2014, 29 (11) : 1434 - 1445
  • [39] Treatment of Parkinson’s Disease: What’s in the Non-dopaminergic Pipeline?
    Albert Y. Hung
    Michael A. Schwarzschild
    [J]. Neurotherapeutics, 2014, 11 : 34 - 46
  • [40] What Is Happening to the Pipeline?
    Senak, Mark
    [J]. AMERICAN HEALTH AND DRUG BENEFITS, 2008, 1 (04): : 54 - 55
12345